Cargando…

Isoniazid and Pulmonary Fibrosis

Detalles Bibliográficos
Autores principales:	Chung, Chae Uk, Park, Dong Il, Lee, Choong Sik, Jung, Sung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2015
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834788/ https://www.ncbi.nlm.nih.gov/pubmed/25698209 http://dx.doi.org/10.4103/0366-6999.151695

Ejemplares similares

Stevens–Johnson Syndrome and Hypothermia Associated with Anti-tuberculosis Medication in a Patient with Heart Failure
por: Jung, Sang-Ok, et al.
Publicado: (2015)

Isoniazid-induced liver disorder in the treatment of tuberculosis
por: Sivannan, Srinivasan, et al.
Publicado: (2018)

Treatment of isoniazid-resistant pulmonary tuberculosis
por: Kim, Yee Hyung, et al.
Publicado: (2008)

Postvaccination Acute Exacerbations of Idiopathic Pulmonary Fibrosis?
por: Huang, Jin-Xian, et al.
Publicado: (2022)

Expression Pattern of the Hippo Pathway Effector TAZ in Cellular and Fibrotic Nonspecific Interstitial Pneumonia
por: Yeo, Min-Kyung, et al.
Publicado: (2018)

Comment on Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults
por: Scholand, Mary Beth, et al.
Publicado: (2022)

Need to confirm isoniazid susceptibility in Xpert MTB/RIF rifampin susceptible cases
por: Vadwai, Viral, et al.
Publicado: (2012)

A Lower Dose of Efavirenz Can Be Coadministered With Rifampicin and Isoniazid in Tuberculosis Patients
por: Kaboggoza, Julian P, et al.
Publicado: (2019)

Treatment of Isoniazid-Resistant Pulmonary Tuberculosis
por: Jhun, Byung Woo, et al.
Publicado: (2020)

Comments on COVID-19 Vaccination and Exacerbation of Idiopathic Pulmonary Fibrosis
por: Kang, Tianlun, et al.
Publicado: (2022)

Novel Insight into Pulmonary Fibrosis and Long COVID
por: Kamp, Jan C., et al.
Publicado: (2023)

Erratum to “Effects of Ammonium Chloride on Ozone-induced Airway Inflammation: the Role of Slc26a4 in the Lungs of Mice”
por: Lee, Jong-Uk, et al.
Publicado: (2021)

Reliability of Mycobacterial Growth Indicator Tube (MGIT) 960 for the detection of isoniazid resistance in a tuberculosis endemic setting
por: Gomathi, N.S., et al.
Publicado: (2014)

Identification of autophagy-related genes in idiopathic pulmonary fibrosis using bioinformatics methods
por: Sun, Shulei, et al.
Publicado: (2022)

Hematopoietic and Lung Platelet Biogenesis as a Prognostic Indicator in Idiopathic Pulmonary Fibrosis
por: Saito, Shigeki, et al.
Publicado: (2022)

Progressive Pulmonary Fibrosis: Putting the Cart Before the Horse
por: Johannson, Kerri A., et al.
Publicado: (2022)

Reply: Transitioning endothelial cells contribute to pulmonary fibrosis
por: Wu, Xiuju, et al.
Publicado: (2023)

Mycobacterial Pulmonary Infections in Patients with Idiopathic Pulmonary Fibrosis
por: Park, Sung-Woo, et al.
Publicado: (2012)

Comparing Transbronchial Cryobiopsy and Surgical Biopsy in Idiopathic Pulmonary Fibrosis
por: Quadrelli, Silvia, et al.
Publicado: (2019)

Progressive Pulmonary Fibrosis: Should the Timelines Be Taken Out of the Definition?
por: Cottin, Vincent, et al.
Publicado: (2022)

Progressive Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis
por: Rose, Jonathan A., et al.
Publicado: (2022)

COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis
por: Sgalla, Giacomo, et al.
Publicado: (2022)

Targeting Pulmonary Hypertension Caused by Pulmonary Fibrosis: A Promising Natural Killer T Cell–based Therapy
por: Wang, Zi-Hao, et al.
Publicado: (2023)

Patient Registries in Idiopathic Pulmonary Fibrosis: Don't Forget Socioeconomic Status
por: Sesé, Lucile, et al.
Publicado: (2020)

Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis
por: Kobayashi, Tetsu, et al.
Publicado: (2020)

Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Bellaye, Pierre-Simon, et al.
Publicado: (2022)

Idiopathic Pulmonary Fibrosis Update: Reconciliation with Hypersensitivity Pneumonitis Guidelines Required?
por: Moran-Mendoza, Onofre
Publicado: (2022)

Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias
por: Suissa, Samy, et al.
Publicado: (2022)

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions
por: Khor, Yet H., et al.
Publicado: (2022)

Peripheral Blood Telomere Attrition in Persons at Risk for Familial Pulmonary Fibrosis
por: Salisbury, Margaret L., et al.
Publicado: (2022)

Functional Criteria to Define Progressive Pulmonary Fibrosis: Searching for the Holy Grail
por: Noboa-Sevilla, María, et al.
Publicado: (2022)

PCSK6: The Endogenous PAR-1 Agonist Driving Pulmonary Fibrosis?
por: Spek, C. Arnold, et al.
Publicado: (2023)

Upregulation of Potassium Voltage-Gated Channel Subfamily J Member 2 Levels in the Lungs of Patients with Idiopathic Pulmonary Fibrosis
por: Lee, Jong-Uk, et al.
Publicado: (2020)

Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial
por: Horita, Nobuyuki, et al.
Publicado: (2020)

Collecting Occupational Exposure Data Would Strengthen Idiopathic Pulmonary Fibrosis Registries
por: Nett, Randall J., et al.
Publicado: (2020)

Reply: Measurement of hypoxia in the lung in idiopathic pulmonary fibrosis: a matter of control
por: Porter, Joanna C., et al.
Publicado: (2022)

Reply to Kamp et al.: Novel Insight into Pulmonary Fibrosis and Long Covid
por: Hatabu, Hiroto, et al.
Publicado: (2023)

Pharmacotherapy and pulmonary fibrosis risk after SARS-CoV-2 infection
por: Zeng, Guangting, et al.
Publicado: (2023)

Erratum: Correction of Figure: Simvastatin Reduces Capsular Fibrosis around Silicone Implants
por: Chung, Kyu Jin, et al.
Publicado: (2016)

The Role of Erythrocyte Membrane Protein Band 4.1-like 3 in Idiopathic Pulmonary Fibrosis
por: Kim, Min Kyung, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a05njnj9jchtnijf8ca7pds7o5